#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2460	16S	1529	1529	99.93	16S.l6.c17.ctg.1	1915	230.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1611	1611	T	264	T	157	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2460	16S	1529	1529	99.93	16S.l6.c17.ctg.1	1915	230.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1345	1345	C	295	C	180	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	2460	16S	1529	1529	99.93	16S.l6.c17.ctg.1	1915	230.0	0	HET	.	.	.	A69G	.	69	69	A	230	230	A	230	A,G	99,46	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4688	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3559	233.0	0	.	n	.	0	G1337A	SNP	1337	1337	G	1609	1609	A	201	A	134	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4688	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3559	233.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2243	2243	C	253	C,G	156,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4688	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3559	233.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2317	2317	A	269	A	163	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4688	23S	2890	2890	99.93	23S.l6.c4.ctg.1	3559	233.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	2869	2869	C	238	C	150	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	184	folP	852	852	99.88	folP.l15.c4.ctg.1	1336	25.0	0	.	p	.	0	E151K	NONSYN	451	453	GAA	595	597	AAA	30;30;30	A;A;A	15;16;16	.	.
folP.WHO_Z_01426c	folP.WHO_Z_01426c	1	1	539	184	folP	852	852	99.88	folP.l15.c4.ctg.1	1336	25.0	1	SNP	p	R228S	1	.	.	682	684	AGC	826	828	AGC	30;30;30	A;G;C	19;19;19	folP.WHO_Z_01426c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	536	gyrA	2751	2291	99.96	gyrA.l6.c4.ctg.1	2565	31.2	1	SNP	p	S91F	0	.	.	271	273	TCC	545	547	TCC	44;44;44	T;C;C	27;28;27	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	536	gyrA	2751	2291	99.96	gyrA.l6.c4.ctg.1	2565	31.2	1	SNP	p	D95G	0	.	.	283	285	GAC	557	559	GAC	47;47;47	G;A;C	29;28;29	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	536	gyrA	2751	2291	99.96	gyrA.l6.c4.ctg.1	2565	31.2	1	SNP	p	D95N	0	.	.	283	285	GAC	557	559	GAC	47;47;47	G;A;C	29;28;29	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	1	536	gyrA	2751	340	100.0	gyrA.l6.c4.ctg.2	678	19.3	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	158	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1350	21.7	1	SNP	p	G45D	0	.	.	133	135	GGC	488	490	GGC	50;50;50	G;G;C	29;28;30	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	106	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	685	27.3	0	.	n	.	0	A197.	DEL	197	197	A	358	358	A	48	A	29	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	456	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2698	30.3	1	SNP	p	D86N	0	.	.	256	258	GAC	411	413	GAC	38;38;38	G;A;C	25;23;25	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	456	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2698	30.3	1	SNP	p	S87I	0	.	.	259	261	AGT	414	416	AGT	38;40;41	A;G;T	25;27;29	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	456	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2698	30.3	1	SNP	p	S87R	0	.	.	259	261	AGT	414	416	AGT	38;40;41	A;G;T	25;27;29	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	456	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2698	30.3	1	SNP	p	S87W	0	.	.	259	261	AGT	414	416	AGT	38;40;41	A;G;T	25;27;29	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	456	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2698	30.3	1	SNP	p	S88P	0	.	.	262	264	TCC	417	419	TCC	41;41;40	T;C;C	28;28;28	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	410	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2492	30.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1499	1501	GGC	21;21;21	G;G;C	13;13;12	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	514	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2319	38.2	1	SNP	p	A311V	0	.	.	931	933	GCA	1298	1300	GCA	55;56;54	G;C;A	34;36;34	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	514	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2319	38.2	1	SNP	p	I312M	0	.	.	934	936	ATC	1301	1303	ATC	55;55;55	A;T;C	36;36;35	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	514	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2319	38.2	1	SNP	p	V316P	0	.	.	946	948	GTG	1313	1315	GTG	56;56;56	G;T;G	35;33;32	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	514	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2319	38.2	1	SNP	p	V316T	0	.	.	946	948	GTG	1313	1315	GTG	56;56;56	G;T;G	35;33;32	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	514	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2319	38.2	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1817	1819	ACC	44;44;42	A;C;C	25;28;26	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	514	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2319	38.2	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1871	1873	GCG	35;35;35	G;C;G	21;18;20	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	514	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2319	38.2	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1871	1873	GCG	35;35;35	G;C;G	21;18;20	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	514	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2319	38.2	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1994	1996	GGC	14;14;16	G;G;C	10;10;9	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	514	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2319	38.2	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2003	2005	GGC	14;14;12	G;G;C	10;10;9	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	514	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2319	38.2	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2021	2023	CTG	15;15;15	C;T;G	11;11;11	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	812	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3312	40.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1667	1669	CCG	26;26;26	C;C;G	17;19;17	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	260	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1729	25.6	0	.	p	.	0	M83fs	FSHIFT	247	247	A	596	596	C	17	C	10	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	306	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1605	36.6	0	.	p	.	0	N38E	NONSYN	112	114	AAT	384	386	GAA	54;53;53	G;A;A	36;35;35	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	306	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1605	36.6	0	.	p	.	0	N134D	NONSYN	400	402	AAT	672	674	GAT	34;35;35	G;A;T	19;19;20	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	306	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1605	36.6	0	.	p	.	0	P175S	NONSYN	523	525	CCA	795	797	TCA	34;34;34	T;C;A	21;21;20	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	306	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1605	36.6	0	.	p	.	0	A218V	NONSYN	652	654	GCC	924	926	GTC	46;44;44	G;T;C	27;27;25	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	306	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1605	36.6	1	SNP	p	G120K	1	.	.	358	360	AAG	630	632	AAG	35;35;35	A;A;G	21;21;21	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	306	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1605	36.6	1	SNP	p	A121D	1	.	.	361	363	GAC	633	635	GAC	35;35;34	G;A;C,A	22;21;19,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	306	porB1b	1047	1047	99.43	porB1b.l15.c4.ctg.1	1605	36.6	1	SNP	p	D121N	0	.	.	361	363	GAC	633	635	GAC	35;35;34	G;A;C,A	22;21;19,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	1222	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	4888	45.2	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	1866	1868	AAT	53;53;53	A;A;T,A	36;36;36,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	98	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1102	19.4	1	SNP	p	V57M	1	.	.	169	171	ATG	647	649	ATG	41;39;40	A;T;G	25;25;26	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
